Paper Review Records
All Paper Review Records
20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
108
days
Increased risk of secondary malignancies after autologous transplantation in R/R follicular lymphoma: Long‐term results from FIL‐FLAZ12 Phase III trial
AuthorsRita Tavarozzi; Andrea Evangelista; Manuela Zanni; Chiara Consoli; Alessandra Tucci; Barbara Botto; Silvia Bolis; Pietro Lauzzana; Vittorio Ruggero Zilioli; Benedetta Puccini; Annalisa Arcari; Vincenzo Pavone; Gloria Margiotta‐Casaluci; Monica Tani; Federica Cavallo; Antonio Pinto; Chiara Ghiggi; Domenico Pastore; Paolo Corradini; Andrés José María Ferreri; Angelo Palmas; Caterina Patti; Francesca Re; Fabio Benedetti; Giuseppe Milone; Stefano Luminari; Elsa Pennese; Elisa Bossi; Carola Boccomini; Antonella Anastasia; Chiara Bottelli; Donato Mannina; Samantha Pozzi; Catello Califano; Luca Arcaini; Flavio Falcinelli; Giuseppe Pietrantuono; Ilaria Del Giudice; Sara Usai; Jacopo Olivieri; Filippo Gherlinzoni; Attilio Olivieri; Tommasina Perrone; Fabrizio Pomponi; Giovannino Ciccone; Umberto Vitolo; Marco Ladetto
Affiliations1. Department of Translational Medicine University of Eastern Piedmont Novara Italy; 2. SCDU of Hematology AOU SS Antonio e Biagio e Cesare Arrigo Alessandria Italy; 3. Unit of Clinical Epidemiology AOU Città Della Salute E Della Scienza Di Torino and CPO Piemonte Turin Italy; 4. Department of Molecular Biotechnology and Health Sciences, Hematology Division University of Torino Turin Italy; 5. Department of Hematology Spedali Civili Brescia Italy; 6. Struttura Complessa Ematologia AOU Città della salute e della scienza di Torino Turin Italy; 7. Division of Haematology SC Ematologia Fondazione Irccs San Gerardo dei Tintori Monza Italy; 8. Division of Hematology, Clinica Ematologica, Centro Trapianti e Terapie Cellulari Carlo Melzi DISM, Azienda Ospedaliero Universitaria S. M. Misericordia Udine Italy; 9. Division of Haematology ASST Grande Ospedale Metropolitano Niguarda Milan Italy; 10. Department of Haematology University of Florence Florence Italy; 11. Division of Hematology AUSL of Piacenza Piacenza Italy; 12. Hematology Unit Ospedale Guglielmo da Saliceto Piacenza Italy; 13. SC of Hematology A. O. C. Panico‐U. O. C Ematologia e Trapianto Tricase Italy; 14. Division of Hematology AOU Maggiore della Carità di Novara Novara Piedmont Italy; 15. Hematology Unit, Department of Oncology and Hematology “Santa Maria delle Croci” Hospital Ravenna Italy; 16. Department of Hematology Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico “Fondazione G Pascale” Naples Italy; 17. IRCCS Azienda Ospedaliera Metropolitana Divisione di Ematologia e Terapie Cellulari Genova Italy; 18. Division of Hematology Ospedale Antonio Perrino Brindisi Italy; 19. Division of Hematology IRCCS Istituto Nazionale Tumori Milan Italy; 20. Lymphoma Unit IUniversity Vita‐Salute San Raffaele Milan Italy; 21. Strategic Program on Lymphomas IRCCS San Raffaele Scientific Institute Milan Italy; 22. Unità di Ematologia e Trapianto di Midollo Osseo, San Francesco Hospital Nuoro Italy; 23. SCDU of Hematology “Villa Sofia – Cervello” Hospital Palermo Italy; 24. Department of Hematology A. O. U. di Parma Parma Italy; 25. Department of Medicine, Section of Hematology and Bone Marrow Transplant Unit University of Verona Verona Italy; 26. Division of Hematology and Program for Hematopoietic Transplantation Azienda Ospedaliera Policlinico Vittorio Emanuele Catania Italy; 27. Hematology Azienda Unità Sanitaria Locale IRCCS of Reggio Emilia Reggio Emilia Italy; 28. SCDU of Hematology Presidio Ospedaliero Pescara Pescara Italy; 29. Hematology Unit Papardo Hospital Messina Messina Italy; 30. Dipartimento di Scienze Mediche e Chirurgiche Materno‐Infantili e dell'Adulto Università di Modena e Reggio Emilia Modena Italy; 31. Hematology Hospital “Andrea Tortora” Pagani Italy; 32. Department of Molecular Medicine University of Pavia Pavia Italy; 33. Division of Hematology Fondazione IRCCS Policlinico San Matteo Pavia Italy; 34. Hematology and Bone Marrow Transplantation Azienda Ospedaliera Di Perugia Perugia Italy; 35. IRCCS CROB Referral Cancer Center of Basilicata Rionero in Vulture Italy; 36. Hematology, Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy; 37. Unit of Hematology and Bone Marrow Transplant AO Brotzu ‐ Ospedale Oncologico Businco Cagliari Italy; 38. Clinica Ematologica Azienda Sanitaria Universitaria Friuli Centrale Udine Italy; 39. Division of Hematology Ca' Foncello Hospital Treviso Italy; 40. SCDU of Hematology Ospedale Regionale delle Marche Ancona Italy; 41. Department of Emergency and Organ Transplantation D. E. T. O., Hematology Section University of Bari Bari Italy; 42. Division of Hematology U.O.C. di Ematologia ‐ AULSS8 Berica Vicenza Italy; 43. Hematology IRCCS Candiolo Cancer Institute Turin Italy
251
days
Venetoclax plus azacitidine, low‐dose cytarabine, aclarubicin, and G‐CSF (VA‐CAG regimen) for newly diagnosed young patients with acute myeloid leukemia: A prospective, multicenter, single‐arm Phase II clinical trial
AuthorsXiaoping Li; Qiurong Zhang; Xiaoyan Li; Lin Liu; Yonglin Shen; Yu Li; Lihui Peng; Chaoyang Zhou; Chie Qiu; Zhongtao Yuan; Shiqian Hou; Youcheng Wang; Lihua Zhang; Jingqiong Li; Liang Zhao; Qiuyuan Tang; Zucong Chen; Jing Feng; Xuejuan Zhang; Guoxiu Bao; Kui Zhang; Renpeng Zhang; Shiqi Li; Yingnian Chen; Jianhua Rao; Yancheng Dong; Dingsong Zhang; Yueyuan Wang; Aifang Li; Xi Ye; Lei Lei; Jiao Chen; Sufen Xu; Yanling Jin; Chaoen Zheng; Yang Liang; Sanbin Wang
Affiliations1. Department of Haematology 920th Hospital of Joint Logistics Support Force Kunming China; 2. Department of Haematology The First Affiliated Hospital of Dali University Dali China; 3. Department of Haematology The People's Hospital of Baoshan Baoshan China; 4. Department of Haematology and Oncology The Southern Central Hospital of Yunnan province Gejiu China; 5. Department of Haematology The People's Hospital of Chuxiong Chongxiong China; 6. Department of Haematology The Northeast Yunnan Center Hospital Zhaotong China; 7. Department of Haematology The People's Hospital of Yuxi City Yuxi China; 8. Department of Haematology and Oncology The People's Hospital of Lijiang Lijiang China; 9. Department of Haematology Xishuangbanna Dai Autonomous Prefecture People's Hospital Jinghong China; 10. Department of Haematology The People's Hospital of Dehong Prefecture Mangshi China; 11. Department of Haematology Dali Bai Autonomous Prefectue People's Hospital Dali China; 12. Department of Haematology The Second People's Hospital of Qujing Qujing China; 13. Department of Haematology The First People's Hospital of Zhaotong Zhaotong China; 14. Department of Haematology and Oncology The People's Hospital of Lincang Lincang China; 15. Department of Haematology Qujing Central Hospital of Yunnan Province Qujing China; 16. Department of Haematology and Rheumatism Immunity The People's Hospital of Puer Puer China; 17. Department of Hematological Oncology, State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat‐sen University Cancer Center Guangzhou China
12
days
Isn't it ironic? Confessions of a pregnant, iron deficient hematologist
AuthorsLauren E. Merz
Affiliations1. Division of Hematology/Oncology, Department of Medicine University of Michigan Ann Arbor MI USA
26
days
The case for targeting enhancer regions in high‐risk TCF3::HLF‐positive B‐cell acute lymphoblastic leukemia
AuthorsZahra Sheybani; Charles E. de Bock
Affiliations1. Children's Cancer Institute Minderoo Children's Comprehensive Cancer Centre Randwick New South Wales Australia; 2. School of Clinical Medicine, Faculty of Medicine UNSW Sydney Sydney New South Wales Australia
78
days
Validation of the new IMS/IMWG consensus genomic staging (CGS) of high‐risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients
AuthorsEfstathios Kastritis; Charalampos Filippatos; Maria Gavriatopoulou; Foteini Theodorakakou; Eirini Solia; Ioannis Ntanasis‐Stathopoulos; Panagiotis Malandrakis; Nikolaos Kanellias; Evangelos Eleutherakis‐Papaiakovou; Magdalini Migkou; Vasiliki Spiliopoulou; Ilias Katsadouros; Aikaterini Vlachou; Despina Fotiou; Konstantinos Giannakas; Erasmia Boutakoglou; Stavroula Giannouli; Panagiotis Tsirigotis; Asimina Papanikolaou; Evangelos Terpos; Meletios A. Dimopoulos
Affiliations1. Department of Clinical Therapeutics, Alexandra General Hospital National and Kapodistrian University of Athens Athens Greece; 2. 2nd Department of Internal Medicine, “Hippokration” General Hospital National and Kapodistrian University of Athens Athens Greece; 3. 2nd Department of Internal Medicine ATTIKON General University Hospital, Hematology Division, National and Kapodistrian University of Athens Athens Greece; 4. Department of Haemopathology “Evangelismos” Hospital Athens Greece
83
days
First‐line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma
AuthorsUmberto Vitolo; Lorenzo Falchi; Per‐Ola Andersson; Marcel Nijland; Fritz Offner; Sylvia Snauwaert; Jacob H. Christensen; Michael R. Clausen; Alexander Fosså; Pilar G. Prieto; Eliza A. Hawkes; Judit M. Jørgensen; Yasmin H. Karimi; Catharina Lewerin; Joost S. P. Vermaat; Björn E. Wahlin; Poliana Patah; Christopher Morehouse; Malene Risum; Zhu Li; Jennifer Marek; Joshua D. Brody
Affiliations1. Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia‐IRCCS Candiolo (Turin) Piedmont Italy; 2. Lymphoma Service, Memorial Sloan Kettering Cancer Center New York New York USA; 3. Section for Hematology and Coagulation Sahlgrenska University Hospital Gothenburg Sweden; 4. Department of Hematology University Medical Center Groningen and University of Groningen Groningen Netherlands; 5. Department of Hematology Universitair Ziekenhuis Gent Ghent Belgium; 6. Department of Hematology AZ Sint‐Jan Hospital Bruges Belgium; 7. Department of Hematology Odense University Hospital Odense Denmark; 8. Department of Hematology and University of Southern Denmark Vejle Hospital Vejle Denmark; 9. Department of Oncology Oslo University Hospital Oslo Norway; 10. Department of Hematology IdiPaz, La Paz University Hospital Madrid Spain; 11. Olivia Newton John Cancer Research Institute at Austin Health Melbourne Victoria Australia; 12. Department of Haematology Aarhus University Hospital Aarhus Midtjylland Denmark; 13. Division of Hematology‐Oncology, Department of Medicine University of Michigan Ann Arbor MI USA; 14. Department of Hematology and Coagulation, Sahlgrenska University Hospital University of Gothenburg Gothenburg Götaland Sweden; 15. Department of Hematology Leiden University Medical Center Leiden Zuid‐Holland Netherlands; 16. Department of Hematology Karolinska Institutet Stockholm Stockholms län Sweden; 17. AbbVie North Chicago Illinois USA; 18. Genmab Plainsboro New Jersey USA; 19. Genmab Copenhagen Hovedstaden Denmark; 20. The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York New York USA
84
days
Therapeutic success and epidemiological failure in hematology
AuthorsPierre Sujobert
Affiliations1. Hospices Civils de Lyon, Hôpital Lyon Sud, Service d'hématologie biologique Lyon France; 2. Faculté de médecine et de maïeutique Lyon Sud Charles Mérieux, Lymphoma Immunobiology Team, Université Claude Bernard Lyon 1 Oullins‐Pierre Bénite France
5
days
Shooting the messenger: Ecosystem approaches in haematology
AuthorsStephen P. Hibbs
Affiliations1. Wolfson Institute of Population Health Queen Mary University of London London United Kingdom
129
days
Clonal and genomic determinants of e1a2 BCR::ABL1 chronic myeloid leukemia: A Fi‐LMC study
AuthorsBenjamin Podvin; Olivier Nibourel; Sandrine Hayette; Valérie Coiteux; Rathana Kim; Lucie Rigolot; Stéphanie Dulucq; Augustin Boudry; Geoffrey Pawlak; Wayne‐Corentin Lambert; Pascale Flandrin‐Gresta; Ivan Sloma; Christophe Roumier; Marie Balsat; Sandrine Loron; Chloé Li; Sandrine Geffroy; Jean‐Michel Cayuela; Françoise Huguet; François‐Xavier Mahon; Franck E. Nicolini; Delphine Réa; Claude Preudhomme; Nicolas Duployez; Catherine Roche‐Lestienne; Fi‐LMC group
Affiliations1. Laboratory of Hematology CHU Lille Lille France; 2. PERSTIM Lab, CRC Lille University of Lille, Inserm Lille France; 3. Institut Bergonié, Fi‐LMC Bordeaux France; 4. Laboratory of Hematology and Molecular Biology, CHU Lyon Sud Pierre‐Bénite France; 5. Hematology Department Huriez Hospital, CHU Lille Lille France; 6. Hematology Laboratory University Hospital Saint‐Louis, AP‐HP and EA3518, Université Paris Cité Paris France; 7. Université Paris Cité, UMR 1342, Institut de Recherche Saint‐Louis, Leukemia Institute Paris Saint‐Louis Paris France; 8. Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole Toulouse France; 9. Laboratory of Hematology, University Hospital of Bordeaux, INSERM U1312 France; 10. ULR 2694 Metrics, Centre Hospitalier Universitaire de Lille Université de Lille Lille France; 11. Laboratory of Hematology, University Hospital of Brest Brest France; 12. Hematology Laboratory University Hospital of Saint‐Etienne St Etienne France; 13. Hematology and Immunology Department AP‐HP Henri Mondor Créteil France; 14. Hematology Department CHU Lyon Sud Lyon France; 15. Hematology Department Hopital National d'Instruction des Armées Percy Clamart France; 16. Hematology Department Institut Universitaire du Cancer de Toulouse Toulouse France; 17. Institut Bergonié Bordeaux, Unicancer Aquitaine France; 18. INSERM Lyon France; 19. Hematology Department Centre Léon Bérard Lyon France; 20. Adult Hematology Department Saint Louis University Hospital Paris France; 21. Genetics Medical Institute, Hopital Jeanne de Flandre Lille France
152
days
Passenger variants as pan‐clonal markers of pediatric AML: Implications for molecular MRD
AuthorsRuth Shiloh; Dana Dayan; Ifat Geron; Maor Cohen; Tamar Feuerstein; Jorge Cano‐Nistal; Nurit Gal‐Mark; Shlomit Barzilai‐Birenboim; Dafna Gaash; Michal Hameiri‐Grossman; Avraham Kahan; Jamal Mahajna; Nino Oniashvili; Hava Rosenfeld; Dan Scharf; Keren Shichrur; Elena Shinderman‐Maman; Sarah Elitzur; Yehudit Birger; Shai Izraeli; Yosef E. Maruvka
Affiliations1. The Rina Zaizov Division of Pediatric Hematology‐Oncology Schneider Children's Medical Center Petah Tikva Israel; 2. Felsenstein Medical Research Center Tel Aviv University, Rabin Medical Center Petah Tikva Israel; 3. Department of Biotechnology and Food Engineering, Technion Haifa Israel; 4. Lokey Center for Life Science and Engineering, Technion Haifa Israel; 5. Department of Biotechnology, Faculty of Sciences Tel‐Hai University of Kiryat Shmona in the Galilee Kiryat Shmona Israel; 6. Gray Faculty of Medical and Health Sciences Tel Aviv University Tel Aviv Israel
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days